Siltuximab is an anti-IL-6 immunoglobulin G-k monoclonal antibody that specifically binds to IL-6 and neutralizes its biological activity; it was approved in the USA in 2014 with restriction to the treatment of Castleman disease (Lyseng-Williamson, 2015). Here, IL6 is linked to Castleman disease.